Drug Trial Radar · NCT03362281
Ilaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients
Last checked: Nov 19, 2026Latest source record: Dec 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
540
Actual
Start
Oct 2014
Primary completion
Apr 2015
Study completion Apr 2015
Sponsor
- Lead sponsor
- Livzon Pharmaceutical Group Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 5, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase study is to confirm the efficacy and safety by compare ilaprazole and omeprazole in the treatment and prevention of peptic ulcer bleeding. Patients with endoscopically diagnosed peptic ulcer bleeding were enrolled in a multi-center, stratified randomized, non-inferiority test, double-blind, parallel and positive-controlled trial. They were randomly assigned into two groups, ilaprazole and omeprazole, to be treated for up to 30 days. The primary endpoint was the hemostasis rate at the end of 72 hours. Secondary end points include ulcer staging changes within 72 hours, effective rate of hemostasis, hemostasis duration, average blood transfusion and rebleeding rate, etc.
Conditions
- Peptic Ulcer Hemorrhage
Interventions
IlaprazoleDrug
10 mg ilaprazole daily (at day 1-3) through intravenous infusion within 30min with first dose doubling.
OmeprazoleDrug
40 mg omeprazole twice daily (at day 1-3) through intravenous infusion within 30min.
Ilaprazole tabletDrug
Since 4th day, those patients were changed to take oral ilaprazole tablets 10mg each day till 30th day
amoxicillin and clarithromycinDrug
The Patients who with helicobacter pylori infection were provided amoxicillin and clarithromycin as complimentary therapy for two weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- the rate of hemostasisTime frame: 72 hours
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.